Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.
Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide.
About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 629 million people by 2045.
Cancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim we are providing new hope for patients by taking cancer on.
Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area.
Living with inflammatory and fibrotic diseases greatly impacts patients’ lives, both physically and emotionally. These patients guide and inspire us to turn innovative science into life-changing medical breakthroughs.
Central nervous system (CNS) diseases, including schizophrenia or Alzheimer’s disease, are a focus of Boehringer Ingelheim discovery research and development.
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases. Visual impairment and blindness have a profound and devastating impact on the lives of the affected person.
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier, too. By delivering value through innovation, we enhance the well-being of both.
IBI Drug Discovery Infographic_04VJ pdf
Card Body : Description Document